OncoMed Pharmaceuticals

OncoMed Pharmaceuticals was a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapeutics that target cancer stem cells (CSCs). The company's research focused on the biology of CSCs, which are believed to be responsible for tumor growth, metastasis, and recurrence. By targeting key signaling pathways such as Notch, Wnt, and RSPO-LGR, OncoMed developed a pipeline of monoclonal antibodies and bispecific agents. The company established significant strategic collaborations with major pharmaceutical firms including Celgene, Bayer, and GSK. In 2019, OncoMed completed a merger with Mereo BioPharma, which integrated its lead oncology assets into Mereo's clinical portfolio.